Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

1-25 of 863 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

Genotype-immunophenotype relationships inNPM1-mutant AML clonal evolution uncovered by single cell multiomic analysis
Drucker M, Lee D, Zhang X, Kain B, Bowman M, Nicolet D, Wang Z, Stone RM, Mrózek K, Carroll AJ, Starczynowski DT, Levine RL, Byrd JC, Eisfeld A, Salomonis N, Grimes HL, Bowman RL, Miles LA
bioRxiv, 12 Nov 2024
Cited by: 0 articles | PPR: PPR938827
Add to export list Preprint
Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia.
Archer KJ, Fu H, Mrózek K, Nicolet D, Mims AS, Uy GL, Stock W, Byrd JC, Hiddemann W, Metzeler KH, Rausch C, Krug U, Sauerland C, Görlich D, Berdel WE, Woermann BJ, Braess J, Spiekermann K, Herold T, Eisfeld AK
Innovation (Camb), 5(6):100719, 21 Oct 2024
Cited by: 0 articles | PMID: 39529956
Add to export list
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.
Hoff FW, Blum WG, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Archer KJ, Patel PA, Collins RH, Baer MR, Duong VH, Arellano ML, Stock W, Odenike O, Redner RL, Kovacsovics T, Deininger MW, [...] Madanat YF
Blood Adv, 8(20):5297-5305, 01 Oct 2024
Cited by: 0 articles | PMID: 39110987 | PMCID: PMC11497398
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Long-term survival can be achieved in a significant fraction of older patients with core binding factor acute myeloid leukemia treated with intensive chemotherapy.
Mosna F, Borlenghi E, Litzow M, Byrd JC, Papayannidis C, Tecchio C, Ferrara F, Marcucci G, Cairoli R, Morgan EA, Gurrieri C, Yeung CCS, Deeg HJ, Capelli D, Candoni A, Gotlib JR, Lunghi M, Pullarkat S, Lanza F, [...] Gottardi M
Haematologica, 10 Oct 2024
Cited by: 0 articles | PMID: 39385741
Add to export list
Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia.
Stiff A, Fornerod M, Kain BN, Nicolet D, Kelly BJ, Miller KE, Mrózek K, Boateng I, Bollas A, Garfinkle EAR, Momoh O, Fasola FA, Olawumi HO, Mencia-Trinchant N, Kloppers JF, van Marle AC, Hu E, Wijeratne S, Wheeler G, [...] Eisfeld AK
Nat Genet, 56(11):2434-2446, 04 Oct 2024
Cited by: 0 articles | PMID: 39367245 | PMCID: PMC11549055
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
CD37 in acute myeloid leukemia: a novel surface target for drug delivery.
Jeremy E, Artiga E, Elgamal S, Cheney CM, Eicher D, Zalponik K, Orwick S, Mao HCC, Wasmuth R, Harrington BK, Mustonen A, Beshay P, Halley P, Castro C, Williams KE, Hing ZA, Chen TL, Lucas CR, Vantangoli NJ, [...] Larkin K
Blood Adv, bloodadvances.2024013590, 30 Sep 2024
Cited by: 0 articles | PMID: 39348689
Add to export list
PTPN11Mutation Clonal Hierarchy in Acute Myeloid Leukemia
Fobare S, Sharpe C, Quinn K, Bryant K, Miles LA, Bowman RL, Cheney C, Furby C, Long M, Fyock K, Wronowski B, Lerma JR, Mullaney A, Mrózek K, Nicolet D, Sesterhenn T, Johnstone ME, Rai SN, Pasare C, [...] Byrd JC
bioRxiv, 20 Sep 2024
Cited by: 0 articles | PPR: PPR913072
Add to export list Preprint
White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia aged <60 years.
Ozga M, Nicolet D, Mrózek K, Walker CJ, Blachly JS, Kohlschmidt J, Orwick S, Carroll AJ, Larson RA, Kolitz JE, Powell BL, Stone RM, Byrd JC, Eisfeld AK, Mims AS
Am J Hematol, 99(11):2236-2240, 16 Sep 2024
Cited by: 0 articles | PMID: 39283025
Add to export list
Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.
Woyach JA, Jones D, Jurczak W, Robak T, Illés Á, Kater AP, Ghia P, Byrd JC, Seymour JF, Long S, Mohamed N, Benrashid S, Lai TH, De Jesus G, Lai R, de Bruin G, Rule S, Munugalavadla V
Blood, 144(10):1061-1068, 01 Sep 2024
Cited by: 3 articles | PMID: 38754046 | PMCID: PMC11406168
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia.
Ravikrishnan J, Diaz-Rohena DY, Muhowski E, Mo X, Lai TH, Misra S, Williams CD, Sanchez J, Mitchell A, Satpati S, Perry E, Kaufman T, Liu C, Lozanski A, Lozanski G, Rogers K, Kittai AS, Bhat SA, Collins MC, [...] Sampath D
Haematologica, 08 Aug 2024
Cited by: 0 articles | PMID: 39113656
Add to export list
Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation.
Gambril JA, Ghazi SM, Sansoterra S, Ferdousi M, Kola-Kehinde O, Ruz P, Kittai AS, Rogers K, Grever M, Bhat S, Wiczer T, Byrd JC, Woyach J, Addison D
Leukemia, 38(10):2141-2149, 17 Aug 2024
Cited by: 0 articles | PMID: 39154059 | PMCID: PMC11436370
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials.
Davids MS, Sharman JP, Ghia P, Woyach JA, Eyre TA, Jurczak W, Siddiqi T, Miranda P, Shahkarami M, Butturini A, Emeribe U, Byrd JC
Blood Adv, 8(13):3345-3359, 01 Jul 2024
Cited by: 0 articles | PMID: 38640349 | PMCID: PMC11255369
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
NOD2 activation enhances macrophage Fcγ receptor function and may increase the efficacy of antibody therapy.
Merchand-Reyes G, Bull MF, Santhanam R, Valencia-Pena ML, Murugesan RA, Chordia A, Mo XM, Robledo-Avila FH, Ruiz-Rosado JD, Carson WE, Byrd JC, Woyach JA, Tridandapani S, Butchar JP
Front Immunol, 15:1409333, 11 Jun 2024
Cited by: 0 articles | PMID: 38919608 | PMCID: PMC11196781
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model.
Archer KJ, Fu H, Mrózek K, Nicolet D, Mims AS, Uy GL, Stock W, Byrd JC, Hiddemann W, Braess J, Spiekermann K, Metzeler KH, Herold T, Eisfeld AK
J Hematol Oncol, 17(1):28, 03 May 2024
Cited by: 0 articles | PMID: 38702786 | PMCID: PMC11068580
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.
Kittai AS, Bond D, Huang Y, Bhat SA, Blyth E, Byrd JC, Chavez JC, Davids MS, Dela Cruz JP, Dowling MR, Duffy C, Ho C, Jacobson C, Jaglowski S, Jain N, Lin KH, Miller C, McCarthy C, Omer Z, [...] Thompson PA
J Clin Oncol, 42(17):2071-2079, 29 Mar 2024
Cited by: 4 articles | PMID: 38552193
Add to export list
Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia.
Elgamal OA, Fobare S, Vibhute S, Mehmood A, Vroom DC, Johnson ML, Stearns B, Lerma JR, Truxall J, Stahl E, Carmichael B, Orwick SJ, Mims AS, Curran E, Santhanam R, Tridandapani S, Phelps MA, Xie Z, Coss CC, [...] Byrd JC
JCI Insight, 9(8):e173646, 22 Apr 2024
Cited by: 0 articles | PMID: 38646934 | PMCID: PMC11141866
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
Woyach JA, Perez Burbano G, Ruppert AS, Miller C, Heerema NA, Zhao W, Wall A, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Stephens DM, Brown JR, Lozanski G, Blachly J, Nattam S, Larson RA, [...] Byrd JC
Blood, 143(16):1616-1627, 01 Apr 2024
Cited by: 2 articles | PMID: 38215395
Add to export list
A Bayesian framework to study tumor subclone-specific expression by combining bulk DNA and single-cell RNA sequencing data.
Qiao Y, Huang X, Moos PJ, Ahmann JM, Pomicter AD, Deininger MW, Byrd JC, Woyach JA, Stephens DM, Marth GT
Genome Res, 34(1):94-105, 07 Feb 2024
Cited by: 2 articles | PMID: 38195207 | PMCID: PMC10903947
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Inhibition of Enhancer of Zeste Homolog 2 Induces Blast Differentiation, Impairs Engraftment and Prolongs Survival in Murine Models of Acute Myeloid Leukemia.
Fobare S, Elgamal OA, Wunderlich M, Stahl E, Mehmood A, Furby C, Lerma JR, Sesterhenn TM, Pan J, Rai J, Johnstone ME, Abdul-Aziz A, Johnson ML, Rai SN, Byrd JC, Hertlein E
Cancers (Basel), 16(3):569, 29 Jan 2024
Cited by: 0 articles | PMID: 38339323 | PMCID: PMC10854504
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.
Woyach JA, Stephens DM, Flinn IW, Bhat SA, Savage RE, Chai F, Eathiraj S, Reiff SD, Muhowski EM, Granlund L, Szuszkiewicz L, Wang W, Schwartz B, Ghori R, Farooqui MZH, Byrd JC
Cancer Discov, 14(1):66-75, 01 Jan 2024
Cited by: 4 articles | PMID: 37930156
Add to export list
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Cai SF, Huang Y, Lance JR, Mao HC, Dunbar AJ, McNulty SN, Druley T, Li Y, Baer MR, Stock W, Kovacsovics T, Blum WG, Schiller GJ, Olin RL, Foran JM, Litzow M, Lin T, Patel P, Foster MC, [...] Stein EM
Blood Adv, 8(2):429-440, 01 Jan 2024
Cited by: 1 article | PMID: 37871309 | PMCID: PMC10827405
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
Ozga M, Nicolet D, Mrózek K, Yilmaz AS, Kohlschmidt J, Larkin KT, Blachly JS, Oakes CC, Buss J, Walker CJ, Orwick S, Jurinovic V, Rothenberg-Thurley M, Dufour A, Schneider S, Sauerland MC, Görlich D, Krug U, Berdel WE, [...] Eisfeld AK
Leukemia, 38(1):45-57, 28 Nov 2023
Cited by: 5 articles | PMID: 38017103 | PMCID: PMC10776397
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization.
Teierle SM, Huang Y, Kittai AS, Bhat SA, Grever M, Rogers KA, Zhao W, Jones D, Byrd JC, Avenarius MR, Heerema NA, Woyach JA, Miller CR
Blood Adv, 7(23):7239-7242, 01 Dec 2023
Cited by: 1 article | PMID: 37851900 | PMCID: PMC10698542
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.
Borate U, Yang F, Press R, Ruppert AS, Jones D, Caruthers S, Zhao W, Vergilio JA, Pavlick DC, Juckett L, Norris B, Bucy T, Burd A, Stein EM, Patel P, Baer MR, Stock W, Schiller G, Blum W, [...] Mims A
Blood Adv, 7(20):6048-6054, 01 Oct 2023
Cited by: 1 article | PMID: 37459200 | PMCID: PMC10582272
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review.
Quartermaine C, Ghazi SM, Yasin A, Awan FT, Fradley M, Wiczer T, Kalathoor S, Ferdousi M, Krishan S, Habib A, Shaaban A, Kola-Kehinde O, Kittai AS, Rogers KA, Grever M, Ruz P, Bhat S, Dickerson T, Byrd JC, [...] Addison D
JACC CardioOncol, 5(5):570-590, 17 Oct 2023
Cited by: 14 articles | PMID: 37969643 | PMCID: PMC10635896
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

1-25 of 863 results

1 2 3 Next ...

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

Genotype-immunophenotype relationships inNPM1-mutant AML clonal evolution uncovered by single cell multiomic analysis

Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia.

Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.

Long-term survival can be achieved in a significant fraction of older patients with core binding factor acute myeloid leukemia treated with intensive chemotherapy.

Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia.

CD37 in acute myeloid leukemia: a novel surface target for drug delivery.

PTPN11Mutation Clonal Hierarchy in Acute Myeloid Leukemia

White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia aged <60 years.

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.

LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia.

Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation.

Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials.

NOD2 activation enhances macrophage Fcγ receptor function and may increase the efficacy of antibody therapy.

Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model.

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.

Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia.

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.

A Bayesian framework to study tumor subclone-specific expression by combining bulk DNA and single-cell RNA sequencing data.

Inhibition of Enhancer of Zeste Homolog 2 Induces Blast Differentiation, Impairs Engraftment and Prolongs Survival in Murine Models of Acute Myeloid Leukemia.

First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.

Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).

Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization.

Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.

Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review.

Partnerships & funding